drugset
Drugs / HTL0039732
last change Jul 2023 re-read 2 minutes ago

HTL0039732

Small molecule

Developed for
cervical cancer · colorectal neoplasm · gastric neoplasm · head and neck neoplasm · kidney neoplasm · lung neoplasm · malignant mesothelioma · neoplasm of esophagus
+5 more · pancreatic neoplasm · pheochromocytoma · prostate cancer · sarcoma · urinary bladder neoplasm
Investigated by
Cancer Research UK · Nxera Pharma UK Limited

Trials 1 · a red edge is where a trial was stopped

today NCT05944237 · Ph 1/2
2024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/2 NCT05944237 Jul 2023 → Jun 2027 expected cervical cancer, colorectal neoplasm, gastric neoplasm, head and neck neoplasm +9 Cancer Research UK Recruiting No outcome recorded

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as HTL0039732 ClinicalTrials.gov intervention name — accepted as the source's own label NCT05944237 ↗
Action Inhibit “HTL0039732 is a small molecule drug that blocks activation of EP4 receptors by prostaglandin E2 (PGE2)” NCT05944237 ↗
Modality Small molecule “HTL0039732 is a small molecule drug” NCT05944237 ↗
Route Oral “HTL0039732 Capsules will be administered orally to fasted participants” NCT05944237 ↗